Welcome to our dedicated page for Scienture Holdings SEC filings (Ticker: SCNX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Scienture Holdings, Inc. (NASDAQ: SCNX) SEC filings page on Stock Titan provides direct access to the company’s regulatory disclosures, including current reports, proxy materials and registration-related documents. Scienture files with the U.S. Securities and Exchange Commission as a Delaware corporation under Commission File Number 001-39199, and its filings offer detailed insight into its specialty pharmaceutical business conducted through its wholly owned subsidiary, Scienture, LLC.
Among the most informative documents for SCNX are current reports on Form 8-K, which describe material events such as financing arrangements, amendments to debt agreements, conversion of secured convertible debentures into common stock, and the issuance of senior secured promissory notes. These filings outline key terms such as principal amounts, original issue discounts, interest rates, security agreements granting liens on company and subsidiary assets, and guaranty obligations. Other 8-Ks address corporate actions including amendments to bylaws, notices from Nasdaq regarding minimum bid price compliance, and results of stockholder votes at the annual meeting.
Scienture’s definitive proxy statement on Schedule 14A is another core filing, setting out proposals submitted to stockholders, including director elections, potential increases in authorized share capital, amendments to the company’s equity incentive plan, authorization for a potential future offering of common stock under Nasdaq Listing Rule 5635(d), and possible reverse stock split authority. The proxy statement also explains governance structures, committee charters and procedures for the annual meeting.
Through Stock Titan, these SEC filings are complemented by AI-powered summaries that highlight the main points of lengthy documents, helping readers quickly understand complex topics such as capital structure changes, equity distribution agreements on Form S-3, or listing compliance matters. Users can review historical and recent filings, monitor how Scienture manages its financing and governance, and reference official disclosures related to its specialty products, including Arbli™ and REZENOPY™. This page is a resource for investors seeking structured, regulator-reviewed information on SCNX beyond press releases and market commentary.
Scienture Holdings, Inc. files its annual report describing a transition into a commercial-stage specialty pharmaceutical company focused on cardiovascular and central nervous system diseases. The company reports an aggregate public float of about $10.2 million and 40,630,815 common shares outstanding as of March 27, 2026.
Subsidiary Scienture LLC leads the business, with its first FDA‑approved product, SCN‑102 losartan potassium oral suspension 10 mg/mL, launched in 2025 as the first approved liquid losartan formulation. It also licensed and will commercialize a high‑dose 10 mg naloxone nasal spray (REZENOPY) under an exclusive U.S. agreement with Kindeva.
The filing outlines a pipeline including SCN‑104 (multi‑dose DHE injection pen for migraine), SCN‑106 (potential Cathflo biosimilar for thrombotic catheter occlusion) and SCN‑107 (long‑acting bupivacaine for post‑surgical pain), supported by multiple IP filings and licensing deals. Extensive risk disclosures highlight funding needs, going‑concern uncertainty, regulatory and IP challenges, Nasdaq listing risks, potential dilution, and high stock price volatility.
Scienture Holdings Co-CEO & Chairman Dr. Shankar Hariharan reported several stock acquisitions and conversions, mainly as equity compensation and prior preferred stock conversions. On February 20, 2026, he was approved for an award of 500,000 restricted shares as a discretionary stock bonus for 2025, to be issued in three tranches of 166,666, 166,667, and 166,667 shares on June 1, September 1, and December 1, 2026, with each tranche vesting three years after issuance. Earlier, he received 750,000 restricted shares on April 14, 2025 and 300,000 restricted shares on October 1, 2025, each vesting in two equal annual installments beginning April 14, 2026 and October 1, 2026, respectively. The filing also shows that on September 19, 2024, his and his spouse’s Series X Non-Voting Convertible Preferred Stock automatically converted into a total of 2,272,296 common shares. In a separate non-market transaction, 30,000 common shares were transferred to a designee of NVK Finance, LLC as consideration for the lender’s consent under a loan amendment. Following the latest award, he directly holds 3,518,679 common shares.
Scienture Holdings, Inc. President & Co-CEO Narasimhan Mani reported multiple equity awards and a prior conversion transaction. On February 20, 2026, the board’s Compensation Committee approved an award of 500,000 restricted common shares as a discretionary stock bonus for 2025 performance, to be issued in three tranches during 2026 and each tranche vesting three years after issuance. Following this award, he holds 1,550,000 common shares directly.
Earlier, he received 750,000 restricted shares on April 14, 2025 and 300,000 restricted shares on October 1, 2025, each vesting in two equal annual installments beginning in 2026. An entity associated with him, Srivatsav, LLC, converted 1,357,538 shares of Series X Non-Voting Convertible Preferred Stock into common stock on September 19, 2024, and later transferred 20,000 common shares to a designee of NVK Finance, LLC as consideration for the lender’s consent to an amended loan agreement.
Scienture Holdings, Inc. (SCNX) announced that it has posted a revised investor presentation on its website and plans to use it in meetings with analysts, potential investors, and other interested parties. The presentation, attached as Exhibit 99.1, provides summary information about the company that should be read together with its reports filed with the SEC.
The company emphasizes that the materials are furnished under Regulation FD, not filed, meaning they are not subject to certain liability provisions of the securities laws and are not automatically incorporated into other SEC filings. The presentation includes forward-looking statements about projects, potential financial performance, and growth opportunities, and the company reminds readers that actual results may differ due to various risks described in its latest Annual Report on Form 10-K for the year ended December 31, 2024 and subsequent Quarterly Reports on Form 10-Q.
Scienture Holdings (SCNX) reported stockholder voting results from its 2025 Annual Meeting. A quorum was present with 10,990,183 votes representing 52.01% of the 21,132,260 shares of common stock entitled to vote.
All five director nominees were elected. Stockholders rejected increasing authorized shares to 2,000,000,000 common and 200,000,000 preferred. They approved increasing the 2019 equity plan reserve from 5,000,000 to 25,000,000 shares, a potential future offering that could exceed 20% of currently outstanding shares at a price below the Nasdaq “minimum price” under Rule 5635(d), and granting the Board discretion to effect a reverse stock split in a range of one‑for‑two to one‑for‑fifty. An adjournment proposal was approved but not used.
These approvals provide flexibility for potential capital transactions and share structure adjustments, while the failure to expand authorized share capital preserves current authorization levels.
Scienture Holdings, Inc. (SCNX) filed a prospectus supplement to its Form S-3, increasing the amount of common stock it is eligible to sell under its equity distribution agreement with Maxim Group LLC to an aggregate offering price of up to $150 million.
According to the filing, $150 million remains available to be sold pursuant to the prospectus supplement. The agreement with Maxim is dated September 19, 2025, and the supplement was filed on November 7, 2025. The notice also states it is not an offer or solicitation where such actions would be unlawful.
Scienture Holdings (SCNX) filed its Q3 2025 report, showing early commercial activity with revenues of $590,050 in the quarter (vs. $64,861 a year ago) and $600,308 for the nine months (vs. $83,560). Gross profit was $574,621 for Q3, but higher operating costs led to an operating loss of $4,361,206 and a net loss of $3,607,361. Weighted average shares were 18.96 million in Q3.
The balance sheet reflects the 2024 Scienture acquisition with $76.4 million in product technology intangibles and $21.37 million of goodwill. Cash was $355,692 at September 30, 2025, and accumulated deficit was $52,430,904. Management disclosed substantial doubt about the company’s ability to continue as a going concern without additional financing.
As part of a strategic realignment, the company sold IPS, Softell and Bonum Health on April 30, 2025 in exchange for a $5,000,000 promissory note (prime rate, balloon due June 30, 2030), recording a $385,528 loss on disposition and $62,500 of interest income. Common shares outstanding were 23,132,260 as of September 30, 2025; the company reports 40,630,815 shares outstanding on November 12, 2025.
Scienture Holdings, Inc. launched an at-the-market equity program to sell up to $150,000,000 of common stock, with Maxim Group LLC as sales agent under its S-3 shelf.
Sales may occur on Nasdaq or through other permitted methods at prevailing prices, and Maxim will earn a 3.0% commission. The company previously sold 15,722,759 shares for gross proceeds of approximately $15,568,236 under earlier supplements. The last reported sale price was $0.75 per share on November 6, 2025.
Shares outstanding were 40,630,815 prior to this program; the filing illustrates a hypothetical post‑offering share count of 240,630,815 if 200,000,000 shares were sold at $0.75. The company’s authorized common stock is 100,000,000 shares and it will not issue above that amount; the board has recommended increasing authorization to 2,000,000,000 shares. Net proceeds are intended for working capital and general corporate purposes, including R&D, commercialization, potential debt repayment, and possible acquisitions.
Scienture Holdings (SCNX) filed a prospectus supplement increasing the amount it may sell under its Form S-3, General Instruction I.B.6, and its equity distribution agreement with Maxim Group LLC to an aggregate offering price of up to $9,592,009.
The company reports it has sold approximately $13,252,250 in gross proceeds of securities under I.B.6 during the prior 12 months. The prospectus supplement states that $9,592,009 remains available to be sold. This notice is not an offer to sell or a solicitation to buy, and any sales would relate to the company’s common stock, par value $0.00001 per share, on permitted terms and in compliant jurisdictions.
Scienture Holdings filed an amended prospectus supplement to register the offer and sale of up to $9,592,009 of common stock, from time to time through Maxim Group LLC under its at-the-market program pursuant to Form S-3.
The amendment increases the amount eligible to be sold under General Instruction I.B.6, which limits primary offerings to no more than one-third of public float while it remains below $75,000,000. The company has sold approximately $13,252,250 during the prior 12 months, leaving $9,592,009 available under the Sales Agreement.
Shares trade on Nasdaq as SCNX; the last reported price was $2.60 per share on October 23, 2025. Shares outstanding were 34,474,230 as of October 23, 2025, and the aggregate market value of non-affiliate holdings used for the I.B.6 calculation was approximately $68,601,377.